Current Knowledge on the Impact of Extracorporeal Blood Purification Devices on Drug Clearance: Systematic Search and Narrative Review
Blood Purification · 19.08.2025 · 54 (12) · 733-744
DOI: 10.1159/000547477 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Blood Purification, online erschienen am 19.08.2025. Verfasst von Rajib Paul und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Apollo Health City, Jubilee Hills, Hyderabad, India. Hauptthemen laut MEDLINE: Anti-Bacterial Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Extracorporeal blood purification (EBP) devices are increasingly used in critically ill patients to manage sepsis, hyperinflammatory states, and other life-threatening conditions. However, these devices may unintentionally remove therapeutic medications, potentially compromising efficacy. Understanding these interactions is essential to optimize therapy and ensure patient safety.
Methods
A systematic search of PubMed, Cochrane, and manufacturer-specific databases was performed to identify literature on drug removal by current adsorptive EBP devices. Studies were screened for evidence of drug clearance, including both preclinical and clinical (in vivo) data, using specific keywords related to drug removal and therapeutic drug monitoring (TDM).
Results
Out of 659 identified articles, 61 met the inclusion criteria. CytoSorb was the most extensively studied device, with 25 relevant publications – 19 of which included in vivo data. Data on drug removal were found for 43 substances with CytoSorb, 8 with Jafron, 12 with oXiris, 25 with Seraph, and 13 with PMX-HP. Antibiotics were the most commonly studied drug class, with vancomycin and meropenem being the most frequently investigated agents. While CytoSorb had the most comprehensive data, evidence for other devices was limited, especially regarding clinical studies.
Conclusions
Adsorptive EBP devices have the potential to unintentionally remove medications, which may compromise therapeutic effectiveness in critically ill patients if not properly accounted for. Among currently available devices, CytoSorb has the most comprehensive evidence base. However, additional clinical studies are required for all devices to confirm findings and establish dosing recommendations. The use of TDM, when available, is strongly advised to guide clinical decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Apollo Health City, Jubilee Hills, Hyderabad, India.
- Department of Critical Care, Nanavati Max Super Speciality Hospital, Mumbai, India.
- Department of Internal Medicine, Universidad del Cauca, Hospital Universitario San José de Popayán, Popayan, Colombia.
- CytoSorbents Europe GmbH, Berlin, Germany.
- Intensive Care Unit, CHU UCL Namur Mont-Godinne, UCL Louvain Medical School, Site Mont Godinne, Yvoir, Belgium, patrick.honore@chuuclnamur.uclouvain.be.
Zitieren
APA
Paul, R., Ansari, A. S., Ballesteros, D., Klaus, T., & Honoré, P. M. (2025). Current Knowledge on the Impact of Extracorporeal Blood Purification Devices on Drug Clearance: Systematic Search and Narrative Review. Blood Purification, 54(12), 733-744. https://doi.org/10.1159/000547477
Vancouver
Paul R, Ansari AS, Ballesteros D, Klaus T, Honoré PM. Current Knowledge on the Impact of Extracorporeal Blood Purification Devices on Drug Clearance: Systematic Search and Narrative Review. Blood Purification. 2025;54(12):733-744. doi:10.1159/000547477
BibTeX
@article{Paul2025,
author = {Paul, Rajib and Ansari, Abdul Samad and Ballesteros, David and Klaus, Teresa and Honoré, Patrick M},
title = {Current Knowledge on the Impact of Extracorporeal Blood Purification Devices on Drug Clearance: Systematic Search and Narrative Review},
journal = {Blood Purification},
year = {2025},
volume = {54},
number = {12},
pages = {733--744},
doi = {10.1159/000547477}
}
EUVIMED